Abstract
The mitochondrial antiviral signaling protein (MAVS) is part of the cell’s innate immune mechanism of defense. MAVS mRNA is bicistronic and can give rise to a full length-MAVS and a shorter isoform termed miniMAVS. In response to viral infections, viral RNA can be sensed by the cytosolic RNA sensors retinoic acid-inducible gene I (RIG-I) and/or melanoma differentiation-associated protein 5 (MDA5) and activate NF-κB through interaction with MAVS. MAVS can also sense cellular stress and activate an anti-oxidative stress (AOS) response through the activation of NF-κB. Because NF-κB is a main cellular transcription factor for HIV-1, we wanted to address what role MAVS plays in HIV-1 reactivation from latency in CD4 T cells. Our results indicate that RIG-I agonists required full length-MAVS whereas the AOS response induced by Dynasore through its catechol group can reactivate latent HIV-1 in a MAVS dependent manner through miniMAVS isoform. Furthermore, we uncover that PKC agonists, a class of latency-reversing agents, induce an AOS response in CD4 T cells and require miniMAVS to fully reactivate latent HIV-1. Our results indicate that the AOS response, through miniMAVS, can induce HIV-1 transcription in response to cellular stress and targeting this pathway adds to the repertoire of approaches to reactivate latent HIV-1 in ‘shock-and-kill’ strategies.
Highlights
Human Immunodeficiency Virus (HIV) is known to establish a latent infection in antiretroviral therapy (ART) treated individuals [1,2,3]
We hypothesized that pharmacological activation of mitochondrial antiviral signaling protein (MAVS) would induce the reactivation of latent HIV-1 through an NF-kB dependent mechanism, and that targeting MAVS may represent a novel strategy toward HIV-1 cure efforts involving “shock and kill” strategies
We demonstrated that different isoforms of MAVS have an important role in HIV-1 reactivation from latency in CD4 T cells mediated by retinoic acid-inducible gene I (RIG-I) ligands, PKC agonists and ROSinducing agents
Summary
Human Immunodeficiency Virus (HIV) is known to establish a latent infection in antiretroviral therapy (ART) treated individuals [1,2,3]. “Shock-and-kill” is one of the most prominent cure strategies currently in development to achieve a sterilizing cure for HIV-1. This strategy is based on eliciting viral gene expression from latently infected cells, allowing for elimination of latently infected cells by virus-mediated cytopathicity or immune-mediated removal by natural killer, CD8 T cells or other immune effectors. A recent work demonstrated that acitretin, a retinoic acid derivative, could reactivate latent HIV-1 and increase levels of RIG-I in a p300-dependent manner. This increase facilitates HIV-1 DNA reduction after reactivation [13].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.